Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: A meta-analysis.
Acute myocardial infarction
Heart failure
Influenza vaccine
Ischaemic heart disease
Meta-analysis
Trial
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
26
05
2023
received:
06
10
2022
accepted:
22
06
2023
medline:
23
10
2023
pubmed:
28
6
2023
entrez:
27
6
2023
Statut:
ppublish
Résumé
Randomized controlled trials (RCTs) enrolling patients at high cardiovascular risk have found that influenza vaccination may reduce the incidence of cardiovascular events. We performed an updated meta-analysis assessing the effect of influenza vaccination on the incidence of cardiovascular events in patients with ischaemic heart disease or heart failure. We searched PubMed, EMBASE and other sources to identify RCTs examining the effect of influenza vaccination on the incidence of cardiovascular events assessed as efficacy outcomes in patients with ischaemic heart disease or heart failure. Eligible studies followed patients for at least one influenza season, defined as a minimum duration of 6 months. The primary endpoint was a composite of cardiovascular death, acute coronary syndrome, stent thrombosis or coronary revascularization, stroke or heart failure hospitalization. The secondary endpoints were cardiovascular death and all-cause death. Two investigators independently identified and extracted data from studies. Results were compared using hazard ratios (HRs) in both random effects and fixed effects models. We included five peer-reviewed and one non peer-reviewed RCTs for a total of 9340 patients. Five trials included patients with ischaemic heart disease (n = 4211) and one trial included patients with heart failure (n = 5129). Influenza vaccination was associated with a reduced incidence of the primary composite endpoint (random effects HR [rHR] 0.74, 95% confidence interval [CI] 0.63-0.88, p < 0.001, I In this meta-analysis of available RCTs in patients at high cardiovascular risk, influenza vaccination was associated with a reduced incidence of cardiovascular events, cardiovascular death and all-cause death as compared to placebo or no treatment.
Types de publication
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1685-1692Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 European Society of Cardiology.
Références
World Health Organization. Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) Accessed 30 May 2022.
Collins SD. Excess mortality from causes other than influenza and pneumonia during influenza epidemics. Public Health Rep. 1932;47:2159-2179. https://doi.org/10.2307/4580606
Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378:345-353. https://doi.org/10.1056/NEJMoa1702090
Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611-2618. https://doi.org/10.1056/NEJMoa041747
Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: A systematic review. Lancet Infect Dis. 2009;9:601-610. https://doi.org/10.1016/S1473-3099(09)70233-6
Ohland J, Warren-Gash C, Blackburn R, Mølbak K, Valentiner-Branth P, Nielsen J, et al. Acute myocardial infarctions and stroke triggered by laboratory-confirmed respiratory infections in Denmark, 2010 to 2016. Euro Surveill. 2020;25:1900199. https://doi.org/10.2807/1560-7917.ES.2020.25.17.1900199
Musher DM, Abers MS, Corrales-Medina VF. Acute infection and myocardial infarction. N Engl J Med. 2019;380:171-176. https://doi.org/10.1056/NEJMra1808137
Kaynar AM, Yende S, Zhu L, Frederick DR, Chambers R, Burton CL, et al. Effects of intra-abdominal sepsis on atherosclerosis in mice. Crit Care. 2014;18:469. https://doi.org/10.1186/s13054-014-0469-1
Madjid M, Vela D, Khalili-Tabrizi H, Casscells SW, Litovsky S. Systemic infections cause exaggerated local inflammation in atherosclerotic coronary arteries. Tex Heart Inst J. 2007;34:11-18.
Behrouzi B, Bhatt DL, Cannon CP, Vardeny O, Lee DS, Solomon SD, et al. Association of influenza vaccination with cardiovascular risk: A meta-analysis. JAMA Netw Open. 2022;5:e228873. https://doi.org/10.1001/jamanetworkopen.2022.8873
Loeb M, Dokainish H, Dans A, Palileo-Villanueva LM, Roy A, Karaye K, et al.; IVVE Investigators. Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design. Am Heart J. 2019;212:36-44. https://doi.org/10.1016/j.ahj.2019.02.009
Influenza Vaccine to Prevent Adverse Vascular Events - IVVE. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2022/04/02/15/50/IVVE. Accessed 26 June 2023
Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al.; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ. 2009;339:b2535. https://doi.org/10.1136/bmj.b2535
Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. https://doi.org/10.1136/bmj.d4002
Fröbert O, Götberg M, Erlinge D, Akhtar Z, Christiansen EH, MacIntyre CR, et al. Influenza vaccination after myocardial infarction: A randomized, double-blind, placebo-controlled, multicenter trial. Circulation. 2021;144:1476-1484. https://doi.org/10.1161/CIRCULATIONAHA.121.057042
Ciszewski A, Bilinska ZT, Brydak LB, Kepka C, Kruk M, Romanowska M, et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J. 2008;29:1350-1358. https://doi.org/10.1093/eurheartj/ehm581
Gurfinkel EP, Leon de la Fuente R, Mendiz O, Mautner B. Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) study. Eur Heart J. 2004;25:25-31. https://doi.org/10.1016/j.ehj.2003.10.018
Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J. 2011;32:1730-1735. https://doi.org/10.1093/eurheartj/ehr004
Keshtkar-Jahromi M, Vakili H, Rahnavardi M. The efficacy of influenza vaccination in reducing cardiovascular events in patients with coronary artery diseases: IVCAD study. Clin Microbiol Infect. 2009;15:S395-S396.
Loeb M, Roy A, Dokainish H, Dans A, Palileo-Villanueva LM, Karaye K, et al.; Influenza Vaccine to Prevent Adverse Vascular Events Investigators. Influenza vaccine to reduce adverse vascular events in patients with heart failure: A multinational randomised, double-blind, placebo-controlled trial. Lancet Glob Health. 2022;10:e1835-e1844. https://doi.org/10.1016/S2214-109X(22)00432-6
Maniar YM, Al-Abdouh A, Michos ED. Influenza vaccination for cardiovascular prevention: Further Insights from the IAMI trial and an updated meta-analysis. Curr Cardiol Rep. 2022;24:1327-1335. https://doi.org/10.1007/s11886-022-01748-8
Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure. Circulation. 2002;106:3068-3072. https://doi.org/10.1161/01.CIR.0000039105.49749.6F
de Simone G, Devereux RB, Chinali M, Lee ET, Galloway JM, Barac A, et al. Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. J Hypertens. 2010;28:353-360. https://doi.org/10.1097/HJH.0b013e3283331169
Daniel M, Jørgensen ME, Gislason G, Jensen JS, Køber L, Claggett B, et al. Influenza vaccine in heart failure. Circulation. 2019;139:575-586. https://doi.org/10.1161/CIRCULATIONAHA.118.036788
Keshtkar-Jahromi M, Vakili H, Rahnavardi M, Gholamin S, Razavi SM, Eskandari A, et al. Antibody response to influenza immunization in coronary artery disease patients: A controlled trial. Vaccine. 2009;28:110-113. https://doi.org/10.1016/j.vaccine.2009.09.108
National Institute for Health and Care Research. PROSPERO: International Prospective Register of Systematic Reviews. https://www.crd.york.ac.uk/prospero. Accessed 26 June 2023.